BioSpace News Archive

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced completion of enrollment in the Phase 3 D-LIVR study evaluating two different treatment regimens containing Lonafarnib.

iSpecimen Inc. today announced that Christopher Ianelli , MD, PhD, CEO and President of iSpecimen, will participate in two upcoming conferences in November 2021

Castor, today announced the acceleration of medical device research & development with its decentralized clinical trial platform to power medical device studies globally.

VBI Vaccines Inc. today announced that its abstract highlighting data from PROTECT, the pivotal Phase 3 immunogenicity and safety study of its 3-antigen prophylactic hepatitis B (HBV) vaccine, was accepted for e-poster presentation at the American Association for the Study of Liver Disease

Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced that its Tablo ® Hemodialysis System has received the first-ever approval from the Centers for Medicare & Medicaid Services (CMS) for a Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES).

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, November 10, 2021, to discuss its third quarter 2021 financial results and provide a business update.

PDS Biotechnology Corporation today announced an agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, PDS0202, a universal flu vaccine candidate.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion chorion membrane (mdHACM) for the treatment of debilitating conditions involving degeneration of connective tissue: osteoarthritis (OA) and tendinopathy.

ASMS 2021 – Biopharmaceutical laboratories can now benefit from high-quality mass information delivered by Orbitrap technology for molecule attribute monitoring in development and quality control (QC).